Oncoinvent ASA (BRRGF) Stock Price & Analysis

59 Followers

BRRGF Stock Chart & Stats

$0.03$0.00(0.00%)

At close: Nov 06 4:00 PM EST

Day’s Range: $0.03 - $0.03
52-Week Range: $0.03 - $0.03
Previous Close: $0.03
Volume: N/A
Average Volume (3M): 0
Market Cap: $40.68M
Enterprise Value: $120.97M
Total Cash (Recent Filing): $140.16M
Total Debt (Recent Filing): $818.00K
Price to Earnings (P/E): ―
Beta: 0.00
Next Earnings: Nov 17, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Oncoinvent ASA News

Oncoinvent bolsters Radspherin programme with Phase 2 progress and NOK 148.5m raise

Oncoinvent ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA reported continued clinical and operational progress, highlighting recruitment of 16 additional patients to its Phase 2 ovarian cancer trial,

1w agoBRRGF 7BG

Oncoinvent sets investor webcast as it advances radiopharmaceutical cancer therapy

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA will host a live webcast for investors, analysts, and other stakeholders on 28 October 2026 at 10:00

2w agoBRRGF 7BG

Oncoinvent Cancels Planned Subsequent Share Offering After Price Slump

Oncoinvent ASA ( ($BRRGF) ) has provided an update. Oncoinvent ASA has decided to cancel its planned subsequent repair offering of up to 200,000 new shares, which was intended to

1M agoBRRGF 7BG

Oncoinvent Completes Private Placement as Linc AB Stake Rises to 12.21%

The latest announcement is out from Oncoinvent ASA ( ($BRRGF) ). Oncoinvent ASA has completed the share capital increase tied to its recent private placement and retail offering of 1,650,000

1M agoBRRGF 7BG

Hadean Ventures Funds Lift Oncoinvent Stake to Over 12% After Private Placement

Oncoinvent ASA ( ($BRRGF) ) has shared an announcement. Oncoinvent ASA has completed a NOK 90-per-share private placement and related share lending arrangements, leading to the re-delivery of 554,327 temporarily

1M agoBRRGF 7BG

Oncoinvent Registers Share Capital Increase After Private Placement

Oncoinvent ASA ( ($BRRGF) ) has provided an announcement. Oncoinvent ASA has completed the registration of a share capital increase following a previously announced private placement and a retail offering,

1M agoBRRGF 7BG

Oncoinvent’s Radspherin Program Gains Spotlight at EANM and ESMO 2026

Oncoinvent ASA ( ($BRRGF) ) has shared an update. Oncoinvent ASA, a clinical-stage radiopharmaceutical developer, is advancing Radspherin[®], an alpha-emitting intraperitoneal therapy aimed at eradicating residual micrometastatic cancer cells following

1M agoBRRGF 7BG

Oncoinvent Details Insider Allocation in Retail Share Offering

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA has announced details related to its previously communicated retail share offering, specifically highlighting the allocation of shares

1M agoBRRGF 7BG

Oncoinvent Shares Begin Trading Ex-Rights Ahead of Planned Offering

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA announced that, as of 23 September 2026, its shares are trading ex-rights, meaning existing and new shareholders

1M agoBRRGF 7BG

Hadean Ventures Funds Adjust Oncoinvent Stake Amid Private Placement Settlement

An update from Oncoinvent ASA ( ($BRRGF) ) is now available. Oncoinvent ASA has completed a private placement of 1,650,000 new shares at NOK 90 per share, triggering a series

1M agoBRRGF 7BG

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on BerGenBio to NOK 38 from NOK 70 and keeps a Buy rating on the shares post the Q2 report.

2y agoBRRGF 7BG0

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

DNB Markets analyst Geir Hiller Holom downgraded BerGenBio to Sell from Hold with a price target of NOK 1, down from NOK 9. The analyst sees the terms of the

3y agoBRRGF 7BG

BerGenBio downgraded to Sell from Hold at DNB Markets

DNB Markets downgraded BerGenBio to Sell from Hold with a NOK 1 price target. Published first on TheFly See today’s best-performing stocks on TipRanks >>

3y agoBRRGF 7BG

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now is an opportune time to step off the sidelines with BerGenBio, with

3y agoBRRGF

BRRGF FAQ

What was Oncoinvent ASA’s price range in the past 12 months?

Oncoinvent ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.

What is Oncoinvent ASA’s market cap?

Oncoinvent ASA’s market cap is $40.68M.

When is Oncoinvent ASA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Oncoinvent ASA’s earnings last quarter?

Oncoinvent ASA released its earnings results on Aug 27, 2026. The company reported -$1.607 earnings per share for the quarter.

Is Oncoinvent ASA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Oncoinvent ASA pay dividends?

Oncoinvent ASA does not currently pay dividends.

What is Oncoinvent ASA’s EPS estimate?

Oncoinvent ASA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oncoinvent ASA have?

Oncoinvent ASA has 6,128,412 shares outstanding.

What happened to Oncoinvent ASA’s price movement after its last earnings report?

Oncoinvent ASA reported an EPS of -$1.607 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Oncoinvent ASA?

Currently, no hedge funds are holding shares in BRRGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oncoinvent ASA

Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.

Oncoinvent ASA (BRRGF) Earnings & Revenues

Historic Earnings Reports

BRRGF Earnings Call

Q2 2026

Earnings Call SentimentPositive

The call conveyed strong operational and clinical momentum: notably accelerated Phase II recruitment, site expansion, positive early clinical signals (low recurrence in Phase I), strengthened IP and scientific visibility, and disciplined near-term financial management. Key risks were also highlighted, including the need for additional funding beyond 2027 to execute Phase III, manufacturing scaling and redundancy needs, increased payroll/regulatory costs, and absence of announced partnerships. On balance, the positives (clear trial progress, regulatory designation, controlled cash burn, and Phase III preparation) outweigh the listed challenges, which are acknowledged and being actively addressed.

View all BRRGF earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	4	3	8
Technical Analysis	2	1	0
Moving Averages	2	2	8

Technical Analysis >

Similar Stocks

Stocks similar to BRRGF
Company	Price & Change	Follow
CLRBCellectar Biosciences
FENCFennec Pharmaceuticals
GERNGeron
KZIAKazia Therapeutics
SRNESorrento Therapeutics

Compare BRRGF Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

BRRGF Stock Chart & Stats

Oncoinvent ASA News

Oncoinvent bolsters Radspherin programme with Phase 2 progress and NOK 148.5m raise

Oncoinvent sets investor webcast as it advances radiopharmaceutical cancer therapy

Oncoinvent Cancels Planned Subsequent Share Offering After Price Slump

Oncoinvent Completes Private Placement as Linc AB Stake Rises to 12.21%

Hadean Ventures Funds Lift Oncoinvent Stake to Over 12% After Private Placement

Oncoinvent Registers Share Capital Increase After Private Placement

Oncoinvent’s Radspherin Program Gains Spotlight at EANM and ESMO 2026

Oncoinvent Details Insider Allocation in Retail Share Offering

Oncoinvent Shares Begin Trading Ex-Rights Ahead of Planned Offering

Hadean Ventures Funds Adjust Oncoinvent Stake Amid Private Placement Settlement

BerGenBio target adjusted to NOK 38 from NOK 70 at H.C. Wainwright

BerGenBio downgraded to Sell on ‘detrimental’ financing at DNB

BerGenBio downgraded to Sell from Hold at DNB Markets

BerGenBio upgraded to Buy from Neutral at H.C. Wainwright

BRRGF FAQ

Company Description

Oncoinvent ASA

Oncoinvent ASA (BRRGF) Earnings & Revenues

BRRGF Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive